Trial Profile
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Dec 2015 New trial record